Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cardiovascular Health Investigation and Collaboration From Countries of America to Assess the Markers and Outcomes of Chagas Disease (CHICAMOCHA-3) - EQUITY (Equivalence of Usual Interventions for Trypanosomiasis)

Next Previous
Trial Profile

Cardiovascular Health Investigation and Collaboration From Countries of America to Assess the Markers and Outcomes of Chagas Disease (CHICAMOCHA-3) - EQUITY (Equivalence of Usual Interventions for Trypanosomiasis)

Status: Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 01 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nifurtimox (Primary) ; Benznidazole
  • Indications Chagas disease
  • Focus Therapeutic Use
  • Acronyms CHICAMOCHA-3; EQUITY

Most Recent Events

  • 18 Jul 2017 Planned End Date changed from 1 Feb 2017 to 1 Feb 2019.
  • 18 Jul 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Aug 2018.
  • 27 Nov 2015 According to ClinicalTrials.gov record, the treatment table has been amended.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top